Scholarlink

<p>Palbociclib (PAL) combined with endocrine therapy (ET) is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2− ) advanced/metastatic breast cancer (MBC). However, there is limited data on the effectiveness of PAL + ET in patients with MBC and low socioeconomic status. This retrospective study of the Flatiron Health database compared overall survival (OS) and real-world progression-free survival (rwPFS) in patients with MBC living in disadvantaged neighborhoods who received either first-line PAL with an aromatase inhibitor (AI) or an AI alone. Of 723 patients, 394 received PAL + AI and 329 received AI alone. After stabilized inverse probability of treatment weighting, median OS was 57.1 months versus 38.2 months (hazard ratio, 0.70, <i>P</i> = 0.0053) and median rwPFS was 19.1 months versus 14.0 months (hazard ratio, 0.66, <i>P</i> = 0.0007) for PAL + AI versus AI alone, respectively. This real-world data analysis demonstrated that first-line PAL + AI versus AI alone was associated with survival benefit in patients with HR+/HER2− MBC living in disadvantaged neighborhoods. Trial registration number: NCT06495164.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月21日

查看全文
  • Filipa Lynce,
  • Xianchen Liu,
  • Benjamin Li,
  • Lynn McRoy,
  • Connie Chen,
  • Raymond Liu,
  • Hope S. Rugo

摘要

Palbociclib (PAL) combined with endocrine therapy (ET) is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2− ) advanced/metastatic breast cancer (MBC). However, there is limited data on the effectiveness of PAL + ET in patients with MBC and low socioeconomic status. This retrospective study of the Flatiron Health database compared overall survival (OS) and real-world progression-free survival (rwPFS) in patients with MBC living in disadvantaged neighborhoods who received either first-line PAL with an aromatase inhibitor (AI) or an AI alone. Of 723 patients, 394 received PAL + AI and 329 received AI alone. After stabilized inverse probability of treatment weighting, median OS was 57.1 months versus 38.2 months (hazard ratio, 0.70, P = 0.0053) and median rwPFS was 19.1 months versus 14.0 months (hazard ratio, 0.66, P = 0.0007) for PAL + AI versus AI alone, respectively. This real-world data analysis demonstrated that first-line PAL + AI versus AI alone was associated with survival benefit in patients with HR+/HER2− MBC living in disadvantaged neighborhoods. Trial registration number: NCT06495164.